148 related articles for article (PubMed ID: 10811676)
1. Phase I pharmacologic study of oral topotecan and intravenous cisplatin: sequence-dependent hematologic side effects.
de Jonge MJ; Loos WJ; Gelderblom H; Planting AS; van der Burg ME; Sparreboom A; Brouwer E; van Beurden V; Mantel MA; Doyle E; Hearn S; Ross G; Verweij J
J Clin Oncol; 2000 May; 18(10):2104-15. PubMed ID: 10811676
[TBL] [Abstract][Full Text] [Related]
2. Phase I and pharmacologic study of continuous infusion topotecan in combination with cisplatin in patients with advanced cancer: a Cancer and LeukemiaGroup B study.
Lilenbaum RC; Miller AA; Batist G; Bernard S; Hollis DR; Rosner GL; Egorin MJ; Schilsky RL; Ratain MJ
J Clin Oncol; 1998 Oct; 16(10):3302-9. PubMed ID: 9779705
[TBL] [Abstract][Full Text] [Related]
3. Phase I trial of intravenous cisplatin-topotecan chemotherapy for three consecutive days in patients with advanced solid tumors: parallel topotecan escalation in two fixed platinum dosing schemes.
Pentheroudakis G; Briasoulis E; Karavassilis V; Mauri D; Tzamakou E; Rammou D; Pavlidis N
Chemotherapy; 2005 May; 51(2-3):154-61. PubMed ID: 15886476
[TBL] [Abstract][Full Text] [Related]
4. Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
Gerrits CJ; Burris H; Schellens JH; Eckardt JR; Planting AS; van der Burg ME; Rodriguez GI; Loos WJ; van Beurden V; Hudson I; Fields S; Von Hoff DD; Verweij J
Clin Cancer Res; 1998 May; 4(5):1153-8. PubMed ID: 9607572
[TBL] [Abstract][Full Text] [Related]
5. Phase I and pharmacologic study of the combination of paclitaxel, cisplatin, and topotecan administered intravenously every 21 days as first-line therapy in patients with advanced ovarian cancer.
Herben VM; Panday VR; Richel DJ; Schellens JH; van der Vange N; Rosing H; Beusenberg FD; Hearn S; Doyle E; Beijnen JH; ten Bokkel Huinink WW
J Clin Oncol; 1999 Mar; 17(3):747-55. PubMed ID: 10071262
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of 3-week schedule of irinotecan combined with cisplatin in patients with advanced solid tumors.
de Jonge MJ; Sparreboom A; Planting AS; van der Burg ME; de Boer-Dennert MM; ter Steeg J; Jacques C; Verweij J
J Clin Oncol; 2000 Jan; 18(1):187-94. PubMed ID: 10623709
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of topotecan and cisplatin in patients with advanced solid tumors: a cancer and leukemia group B study.
Miller AA; Hargis JB; Lilenbaum RC; Fields SZ; Rosner GL; Schilsky RL
J Clin Oncol; 1994 Dec; 12(12):2743-50. PubMed ID: 7527456
[TBL] [Abstract][Full Text] [Related]
8. Phase I pharmacokinetic and pharmacodynamic study of Carboplatin and topotecan administered intravenously every 28 days to patients with malignant solid tumors.
Boss DS; Siegel-Lakhai WS; van Egmond-Schoemaker NE; Pluim D; Rosing H; Ten Bokkel Huinink WW; Beijnen JH; Schellens JH
Clin Cancer Res; 2009 Jul; 15(13):4475-83. PubMed ID: 19531625
[TBL] [Abstract][Full Text] [Related]
9. A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin).
Gerrits CJ; Schellens JH; Burris H; Eckardt JR; Planting AS; van der Burg ME; Rodriguez GI; Loos WJ; van Beurden V; Hudson I; Von Hoff DD; Verweij J
Clin Cancer Res; 1999 Jan; 5(1):69-75. PubMed ID: 9918204
[TBL] [Abstract][Full Text] [Related]
10. Dose and schedule-finding study of oral topotecan and weekly cisplatin in patients with recurrent ovarian cancer.
Gelderblom H; Sparreboom A; de Jonge MJ; Loos WJ; Wilms E; Mantel MA; Hennis B; Camlett I; Verweij J; van der Burg ME
Br J Cancer; 2001 Oct; 85(8):1124-9. PubMed ID: 11710824
[TBL] [Abstract][Full Text] [Related]
11. Phase-I dose escalation and sequencing study of docetaxel and continuous infusion topotecan in patients with advanced malignancies.
Posey JA; Wang H; Hamilton J; Delgrosso A; Zhang R; Freda T; Zamboni WC
Cancer Chemother Pharmacol; 2005 Aug; 56(2):182-8. PubMed ID: 15838660
[TBL] [Abstract][Full Text] [Related]
12. A Phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma.
Mok TS; Wong H; Zee B; Yu KH; Leung TW; Lee TW; Yim A; Chan AT; Yeo W; Chak K; Johnson P
Cancer; 2002 Oct; 95(7):1511-9. PubMed ID: 12237920
[TBL] [Abstract][Full Text] [Related]
13. Phase I study of daily times five topotecan and single injection of cisplatin in patients with previously untreated non-small-cell lung carcinoma.
Raymond E; Burris HA; Rowinsky EK; Eckardt JR; Rodriguez G; Smith L; Weiss G; Von Hoff DD
Ann Oncol; 1997 Oct; 8(10):1003-8. PubMed ID: 9402174
[TBL] [Abstract][Full Text] [Related]
14. Phase I and pharmacokinetic study of the combination of topotecan and ifosfamide administered intravenously every 3 weeks.
Kerbusch T; Groenewegen G; Mathôt RA; Herben VM; ten Bokkel Huinink WW; Swart M; Ambaum B; Rosing H; Jansen S; Voest EE; Beijnen JH; Schellens JH
Br J Cancer; 2004 Jun; 90(12):2268-77. PubMed ID: 15150579
[TBL] [Abstract][Full Text] [Related]
15. Sequences of topotecan and cisplatin: phase I, pharmacologic, and in vitro studies to examine sequence dependence.
Rowinsky EK; Kaufmann SH; Baker SD; Grochow LB; Chen TL; Peereboom D; Bowling MK; Sartorius SE; Ettinger DS; Forastiere AA; Donehower RC
J Clin Oncol; 1996 Dec; 14(12):3074-84. PubMed ID: 8955652
[TBL] [Abstract][Full Text] [Related]
16. Prolonged topotecan infusion with cisplatin in the first-line treatment of ovarian cancer: an NYGOG and ECOG study.
Hochster HS; Plimack ER; Mandeli J; Wadler S; Runowicz C; Goldberg G; Speyer J; Wallach R; Muggia F;
Gynecol Oncol; 2006 Feb; 100(2):324-9. PubMed ID: 16253316
[TBL] [Abstract][Full Text] [Related]
17. Sequencing topotecan and etoposide plus cisplatin to overcome topoisomerase I and II resistance: a pharmacodynamically based Phase I trial.
Aisner J; Musanti R; Beers S; Smith S; Locsin S; Rubin EH
Clin Cancer Res; 2003 Jul; 9(7):2504-9. PubMed ID: 12855624
[TBL] [Abstract][Full Text] [Related]
18. Phase 1/pharmacology study of intraperitoneal topotecan alone and with cisplatin: potential for consolidation in ovarian cancer.
Andreopoulou E; Chen T; Liebes L; Curtin J; Blank S; Wallach R; Hochster H; Muggia F
Cancer Chemother Pharmacol; 2011 Aug; 68(2):457-63. PubMed ID: 21069334
[TBL] [Abstract][Full Text] [Related]
19. Effective dosing of topotecan with carboplatin in relapsed ovarian cancer: a phase I/II study.
Bowman A; Rye T; Ross G; Wheatley A; Smyth JF
J Clin Oncol; 2001 Jul; 19(13):3255-9. PubMed ID: 11432893
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of docetaxel and topotecan in patients with advanced malignancies.
Dubey S; Hutson P; Alberti D; Arzoomanian R; Binger K; Volkman J; Feierabend C; Wilding G; Schiller JH
J Oncol Pharm Pract; 2005 Dec; 11(4):131-8. PubMed ID: 16595064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]